ClinicalTrials.gg
RecruitingNCT05143996Updated Oct 28, 2026

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

A Phase 1/2 interventional study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and TP53-mutated MDS and AML, sponsored by Cullinan Therapeutics Inc.. Recruiting at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Cullinan Therapeutics Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2021; still recruiting 5 years later.
Updated Oct 28, 2026Primary completion movedStudy completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
275
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States — 311 open to participants now, 465 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Planned enrollment
107th of 1,907
275 · median 35
Started
2021
with 90 others
Phase 1/2
306 of 2,137
47 open now
Primary completion
2029-12
later than 410 of 463 live
Registered
1,812th of 2,137
by date

Among the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 107th largest by planned enrollment of the 1,907 interventional ones that give a count, is one of 91 that started in 2021, is one of 306 in phase 1/2, reaches primary completion later than 410 of the 463 other live ones, and was the 1,812th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

311 of the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

306 more — sign in →

All 311 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 621 Leukemia, Myeloid, Acute studies recruiting now, 361 (58%) set no upper age limit and 220 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

CLN-049-001 is a Phase 1/2, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Read the detailed description

This trial is divided into 5 parts:

Part A - Single Ascending Dose (SAD) - Patients will receive a single dose of CLN-049 via IV administration and be followed for safety for 28 days

Part B - Multiple Ascending Dose (MAD) - Patients will receive CLN-049 every 7 days (q7d) after an initial Lead-In Dose via IV administration and be followed for safety for 28 days and will then enter long-term follow-up for up to 2 years

Part C - Multiple Ascending Dose (MAD) - Patients will receive CLN-049 q7d via SC injection and be followed for safety for 28 days and will then enter long-term follow-up for up to 2 years

Part D - a Phase 2 Dose Optimization and Expansion of IV administered CLN-049 - patients will be randomized 1:1 to one of two dose regimens derived from doses tested during Part B (MAD-IV). Following selection of the RP2D in Dose Optimization, additional patients will be enrolled at the RP2D in Expansion.

Part E - a Phase 2 Dose Expansion of IV administered CLN-049 - an exploratory hypothesis-generating expansion cohort that will test CLN-049 at the RP2D (as determined in Part D Dose Optimization) in newly diagnosed, previously untreated AML patients with TP53 mutations.

Enrollment in Part A concluded in May 2022. Enrollment in Part C concluded in July 2024.

03

Conditions studied

  • Relapsed/Refractory Acute Myeloid Leukemia (AML)
  • Myelodysplastic Syndrome (MDS)
  • TP53-mutated MDS and AML
04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 18 years of age.
  2. Patient has a confirmed diagnosis of recurrent or AML or MDS:

    Parts A, B, C:

    i. AML either de novo or secondary ii. MDS with at least 5% blasts that is relapsed after or refractory to hypomethylating agent (HMA) therapy iii. Patient has received, and has progressed, recurred, or is intolerant of approved therapeutic options that are available or declines treatment with these therapies

    Part D:

    i. Confirmed diagnosis of de novo or secondary R/R AML (includes patients with MDS/AML) ii. Patient has received no more than 2 iii. Patients must have exhausted, be ineligible for, be intolerant of, or otherwise not be considered appropriate candidates for available therapies considered suitable for the individual patient (including targeted therapies) iv. Patients must have a recent assessment of TP53 mutation status by an approved local laboratory.

    Part E:

    i. Patient has a confirmed diagnosis of de novo or secondary newly diagnosed AML (includes patients with MDS/AML) with no prior lines of AML-directed therapy ii. Patient must have evidence of a positive recent assessment of TP53 mutation status

  3. White blood cell (WBC) count at the time of the first dose is \< 20,000/uL
  4. (ECOG) performance status is 0 to 2.
  5. Toxicities related to prior study therapy should have resolved to Grade 1 or less according to criteria of v5.0
  6. The patient's laboratory values meet the following criteria:

    1. (CrCl) as calculated by the Cockcroft-Gault formula must be ≥ 45 mL/min;
    2. Total ≤ 1.5 × .
    3. and ALT ≤ 3.0 × ULN (unless attributed to leukemic involvement).

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of acute promyelocytic leukemia (APL)
  2. Active central nervous system (CNS) leukemia.
  3. Isolated extramedullary relapse
  4. Prior organ allograft
  5. Prior history of hematopoietic transplantation:

    1. In Parts A, B, and C: Prior history of allogeneic hematopoietic transplantation within six months of treatment or with clinical or laboratory evidence of , or requiring ongoing treatment with immune suppression
    2. In Parts D and E: Prior history of allogeneic hematopoietic transplantation within twelve months of treatment or with clinical or laboratory evidence of GVHD, or requiring ongoing treatment with immune suppression
  6. Treatment with any of the following:

    1. Radiation therapy (XRT) within 28 days of the first dose of CLN-049, or craniospinal XRT within 8 weeks of the first dose of CLN-049, or history of total body irradiation (TBI).
    2. Prior immunotherapy with ≤ 42 days prior to the first dose of CLN-049.
    3. Prior history of chimeric antigen receptor (CAR-T) cell therapy or other modified T cell therapy.
    4. Anti-leukemic therapy except hydroxyurea for cytoreduction, and intrathecal chemotherapy ≤ 14 days or 5 half-lives, whichever is shorter, prior to the first dose of CLN-049.
    5. Short-acting hematopoietic growth factors ≤ 7 days prior to the first dose of CLN-049
    6. Long-acting growth factors ≤ 14 days prior to the first dose of CLN-049.
    7. Systemic therapy (except equivalent of \< 10 mg prednisone daily) or other immune-suppressive drugs ≤ 14 days prior to the first dose of CLN-049
    8. Prior treatment with a FLT3-directed bispecific molecule, or a FLT3-targeted antibody.
  7. Currently participating/previously participated in an interventional study and received an drug within 14 days (or five half-lives, whichever is longer) prior to the first dose of CLN-049.
  8. Patients with concomitant second requiring active treatment in the past 12 months, or if additional therapy is required or anticipated during study participation.
  9. Patients with any active disease or a history of known or suspected autoimmune disease, or history of a syndrome that requires systemic corticosteroids or medications
  10. A serious uncontrolled medical disorder that would impair the ability of the patient to receive protocol therapy or whose control may be jeopardized by the complications of this therapy.
  11. Any concurrent condition, therapy, or laboratory abnormality that, in the opinion of the investigator, might compromise patient safety or interfere with the evaluation of the safety of the drug.
  12. Active uncontrolled infection within seven days of first dose of CLN-049.
  13. Has a history of, or a positive test for (HIV) 1/2 or primary immunodeficiency disease such as HIV.
  14. Known history of (with positive testing for either hepatitis B surface antigen [HBsAg] or hepatitis B core Ab), (HCV) infection (with positive testing for HCV antibody and/or HCV ribonucleic acid [RNA] in serum), or acute hepatitis A (with positive testing for hepatitis A IgM).
  15. Active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
  16. History of the following events in conjunction with prior treatment with immunotherapy: Grade 3 or greater neurotoxicity, ocular toxicity, pneumonitis, myocarditis, or colitis; liver dysfunction meeting the laboratory criteria for Hy's Law.
  17. within 28 days of the first dose of CLN-049, during treatment, and until the end of last dose of CLN-049.
  18. corrected for heart rate using Fridericia's formula (QTcF) of ≥ 480 milliseconds.
  19. Patient has history of drug-related anaphylactic reactions to any components of CLN-049. History of Grade 4 anaphylactic reaction to any bispecific molecule or monoclonal antibody therapy.
  20. Known history of prior human anti-human antibody response. Patients will not be screened for human anti-human antibody prior to study participation.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
275 participants (estimated)

Study arms

  • Experimental
    Part A - Single ascending dose (SAD) design of IV administered CLN-049

    Patients with relapsed/refractory AML or MDS will receive CLN-049 via IV administration

    Drug: CLN-049

  • Experimental
    Part B - Multiple ascending dose (MAD) design of IV administered CLN-049

    Patients with relapsed/refractory AML or MDS will receive CLN-049 via IV administration

    Drug: CLN-049

  • Experimental
    Part C - Multiple ascending dose (MAD) design of SC administered CLN-049

    Patients with relapsed/refractory AML or MDS will receive CLN-049 via SC injection

    Drug: CLN-049

  • Experimental
    Part D - Phase 2 Dose Optimization and Expansion

    Dose Optimization: patients will be randomized 1:1 to one of two dose regimens of CLN-049 via IV derived from doses tested during Part B (MAD-IV). Dose Expansion: patients will receive a single dose regimen of CLN-049 via IV as determined by Dose Optimization (RP2D).

    Drug: CLN-049

  • Experimental
    Part E - Expansion of IV-administered CLN-049 in newly diagnosed AML patients with TP53 mutations

    Newly diagnosed, previously untreated AML patients with TP53 mutations will receive a single dose regimen of CLN-049 via IV as determined by Dose Optimization (RP2D).

    Drug: CLN-049

Interventions

  • DrugCLN-049

    \[FLT3\] x \[CD3\] bispecific T cell engager

06

What researchers measure

Primary outcomes

  1. Number of treatment emergent events (TEAEs)

    TEAEs will be defined as adverse events that are reported for the first time following study drug administration for worsening of a pre-existing event after the first dose

    Time frame: 28 days

  2. Cmax of CLN-049

    Maximum drug concentration

    Time frame: Up to 13 weeks

  3. Ctrough of CLN-049

    The observed plasma concentration just prior to the beginning of, or at the end of a dosing interval

    Time frame: 28 Days

  4. Tmax of CLN-049

    Time to Cmax

    Time frame: 28 Days

  5. T1/2 of CLN-049

    28 Days

    Time frame: Up to 28 days

  6. Efficacy of CLN-049

    CR (complete response) + CRh (complete remission with partial hematologic recovery) rate

    Time frame: Up to 13 weeks

07

Study locations

9 of 17 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Dec 2029, 97 months after the start.

Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's planned 97 months is above that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Jan 2027 → Dec 2029 and completion Jun 2027 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2021
First posted
Dec 3, 2021
StartActual
Nov 18, 2021
Primary completionEst.
Dec 30, 2029was Jan 2027
CompletionEst.
Dec 30, 2029was Jun 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added
Show 6 added (6 United States)
  • Mayo Clinic Hospital - Phoenix · Phoenix, United States
  • City of Hope · Duarte, United States
  • UCHealth Anschutz Cancer Pavilion · Aurora, United States
  • Mayo Clinic Hospital - Jacksonville · Jacksonville, United States
  • Mayo Clinic Hospital - Rochester · Rochester, United States
  • New York-Presbyterian / Weill Cornell Medical Center · New York, United States
Oct 28, 2026
Primary completion
Jan 2027→Dec 30, 2029
Oct 28, 2026
Study completion
Jun 2027→Dec 30, 2029
Oct 28, 2026
Enrollment
60→275
Oct 28, 2026
Eligibility
4 inclusion criteria edited, 6 added, 2 removed; 8 exclusion criteria edited, 2 added, 4 removed
What changed in the criteria
Inclusion criteria
  • RemovedWilling and able to give written informed consent and adhere to protocol requirements; written informed consent and any locally required authorization must be obtained from the patient prior to performing any protocol-related procedures, including screening evaluations, and serial samples of bone marrow and peripheral blood.
  • AddedParts A, B, C:
  • EditedAML either de novo or secondary ii. MDS with at least 5% blasts that is relapsed after or refractory to hypomethylating agent (HMA) therapy iii. Patient has received, and has progressed, recurred, or is intolerant of approved therapeutic options that are available, or declines treatment with these therapies.
  • RemovedWhite blood cell (WBC) count at the time of the first dose is < 20,000/uL (hydroxyurea is permitted according to standard institutional practice). Following first dose, WBC should be checked prior to subsequent CLN-049 administration and if WBC > 20,000/μL, CLN-049 treatment should be postponed (see Section 6.1 for further guidance).
  • AddedPart D:
  • AddedConfirmed diagnosis of de novo or secondary R/R AML (includes patients with MDS/AML) ii. Patient has received no more than 2 prior lines of therapy iii. Patients must have exhausted, be ineligible for, be intolerant of, or otherwise not be considered appropriate candidates for available therapies considered suitable for the individual patient (including targeted therapies) iv. Patients must have a recent assessment of TP53 mutation status by an approved local laboratory.
  • AddedPart E:
  • AddedPatient has a confirmed diagnosis of de novo or secondary newly diagnosed AML (includes patients with MDS/AML) with no prior lines of AML-directed therapy ii. Patient must have evidence of a positive recent assessment of TP53 mutation status
  • AddedWhite blood cell (WBC) count at the time of the first dose is < 20,000/uL
  • EditedToxicities related to prior study therapy should have resolved to Grade 1 or less according to criteria of NCI CTCAE v5.0, except for alopecia, lymphopenia, neutropenia, leukopenia, anemia, thrombocytopenia. Patients with chronic but stable toxicities may be allowed to enroll after agreement between the Investigator and Sponsor.
  • EditedCreatinine clearance (CrCl) as calculated by the Cockcroft-Gault formula (Appendix 1) must be ≥ 6045 mL/min;
  • ChangedBefore Total bilirubin ≤ 1.5 × ULN. This does not apply for patients with confirmed Gilbert's Syndrome, hemolysis, or chronic blood transfusions, for whom total bilirubin must be less than 3.0 mg/dL with a conjugated bilirubin less than 0.5 mg/dL;Now Total bilirubin ≤ 1.5 × ULN.
Exclusion criteria
  • ChangedBefore Active central nervous system (CNS) leukemia. For patients with a history of CNS leukemia, a lumbar puncture should be performed during screening to exclude the presence of active CNS involvement.Now Active central nervous system (CNS) leukemia.
  • AddedPrior history of allogeneic hematopoietic transplantation:
  • EditedAllogeneicIn Parts A, B, and C: Prior history of allogeneic hematopoietic transplantation within six months of treatment, or with clinical or laboratory evidence of GVHD, or requiring ongoing treatment with immune suppression within 2 months of the first dose of CLN-049.
  • AddedIn Parts D and E: Prior history of allogeneic hematopoietic transplantation within twelve months of treatment or with clinical or laboratory evidence of GVHD, or requiring ongoing treatment with immune suppression
  • EditedRadiation therapy (XRT) within 28 days of the first dose of CLN049CLN-049, or craniospinal XRT within 8 weeks of the first dose of CLN-049, or history of total body irradiation (TBI).
  • EditedSystemic glucocorticoid therapy (except equivalent of < 10 mg prednisone daily) or other immune-suppressive drugs ≤ 14 days prior to the first dose of CLN-049 (see separate guidelines for patients who are post allogeneic hematopoietic transplantation). The transient use of corticosteroids for transfusion premedication or the treatment of infusion or transfusion reactions will not be considered for this criterion. Topical corticosteroids and steroid eye drops are allowed, and will not exclude the patient from eligibility.
  • EditedPatients with any active autoimmune disease or a history of known or suspected autoimmune disease, or history of a syndrome that requires systemic corticosteroids or immunosuppressive medications, except for patients with vitiligo, psoriasis (in consultation with the Sponsor), resolved childhood asthma/atopy or autoimmune thyroid disorders on stable thyroid hormone supplementation.
  • EditedActive uncontrolled infection within seven days of first dose of CLN-049. Prophylactic use of systemic antiviral, antibacterial, or antifungal agents for treatment of chronic, controlled infection or as prophylaxis is permitted.
  • EditedKnown history of hepatitis B (with positive testing for either hepatitis B surface antigen [HBsAg] or hepatitis B core Ab), hepatitis C (HCV) infection (with positive testing for HCV antibody and/or HCV ribonucleic acid [RNA] in serum), or acute hepatitis A (with positive testing for hepatitis A IgM). Note: patients with chronic HCV with undetectable viral load defined by sustained virologic response 24 weeks (SVR24) after completion of anti-hepatitis C treatment will be eligible. Patients with hepatitis B surface antigen [HBsAg] or hepatitis B core Ab with negative viral load will be eligible.
  • ChangedBefore Active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection including history of positive SARS-CoV-2 testing without subsequent documentation of negative test results, patients with results that are pending but not yet known, or patients with suspected active infection based on clinical featuresNow Active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
  • RemovedWoman of child-bearing potential (WOCBP) who is pregnant or breast-feeding, plans to become pregnant within 120 days of last study drug administration, or declines to use an acceptable method to prevent pregnancy during study treatment and for 120 days after the last dose of study drug administration.
  • RemovedMale patient who plans to father a child or donate sperm within 120 days of last study drug administration, or who has a partner who is a WOCBP, and declines to use acceptable method to prevent pregnancy during study treatment and for 120 days after the last dose of study drug administration.
  • RemovedKnown active alcohol or drug abuse.
  • RemovedPatients who are incapacitated or involuntarily incarcerated.
Oct 28, 2026
Interventions
Arms added: Part D - Phase 2 Dose Optimization and Expansion·Part E - Expansion of IV-administered CLN-049 in newly diagnosed AML patients with TP53 mutations
Oct 28, 2026
Primary outcomes
1 time frame changed, 1 added
What changed in the outcomes
  • AddedEfficacy of CLN-049Time frame: Up to 13 weeks
  • Time frameCmax of CLN-04928 Days → Up to 13 weeks
Oct 28, 2026
Secondary outcomes
1 removed
What changed in the outcomes
  • RemovedImmunogenicity of CLN-049Time frame: 28 days
Oct 28, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Emory University Hospital · Atlanta, United StatesContact person changed (no phone or email listed)
Oct 28, 2026
Design
Added Phase 2
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    6 sites added
    Show 6 added (6 United States)
    • Mayo Clinic Hospital - Phoenix · Phoenix, United States
    • City of Hope · Duarte, United States
    • UCHealth Anschutz Cancer Pavilion · Aurora, United States
    • Mayo Clinic Hospital - Jacksonville · Jacksonville, United States
    • Mayo Clinic Hospital - Rochester · Rochester, United States
    • New York-Presbyterian / Weill Cornell Medical Center · New York, United States
    Primary completion Jan 2027→Dec 30, 2029
    Study completion Jun 2027→Dec 30, 2029
    Enrollment 60→275
    Eligibility 4 inclusion criteria edited, 6 added, 2 removed; 8 exclusion criteria edited, 2 added, 4 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedWilling and able to give written informed consent and adhere to protocol requirements; written informed consent and any locally required authorization must be obtained from the patient prior to performing any protocol-related procedures, including screening evaluations, and serial samples of bone marrow and peripheral blood.
    • AddedParts A, B, C:
    • EditedAML either de novo or secondary ii. MDS with at least 5% blasts that is relapsed after or refractory to hypomethylating agent (HMA) therapy iii. Patient has received, and has progressed, recurred, or is intolerant of approved therapeutic options that are available, or declines treatment with these therapies.
    • RemovedWhite blood cell (WBC) count at the time of the first dose is < 20,000/uL (hydroxyurea is permitted according to standard institutional practice). Following first dose, WBC should be checked prior to subsequent CLN-049 administration and if WBC > 20,000/μL, CLN-049 treatment should be postponed (see Section 6.1 for further guidance).
    • AddedPart D:
    • AddedConfirmed diagnosis of de novo or secondary R/R AML (includes patients with MDS/AML) ii. Patient has received no more than 2 prior lines of therapy iii. Patients must have exhausted, be ineligible for, be intolerant of, or otherwise not be considered appropriate candidates for available therapies considered suitable for the individual patient (including targeted therapies) iv. Patients must have a recent assessment of TP53 mutation status by an approved local laboratory.
    • AddedPart E:
    • AddedPatient has a confirmed diagnosis of de novo or secondary newly diagnosed AML (includes patients with MDS/AML) with no prior lines of AML-directed therapy ii. Patient must have evidence of a positive recent assessment of TP53 mutation status
    • AddedWhite blood cell (WBC) count at the time of the first dose is < 20,000/uL
    • EditedToxicities related to prior study therapy should have resolved to Grade 1 or less according to criteria of NCI CTCAE v5.0, except for alopecia, lymphopenia, neutropenia, leukopenia, anemia, thrombocytopenia. Patients with chronic but stable toxicities may be allowed to enroll after agreement between the Investigator and Sponsor.
    • EditedCreatinine clearance (CrCl) as calculated by the Cockcroft-Gault formula (Appendix 1) must be ≥ 6045 mL/min;
    • ChangedBefore Total bilirubin ≤ 1.5 × ULN. This does not apply for patients with confirmed Gilbert's Syndrome, hemolysis, or chronic blood transfusions, for whom total bilirubin must be less than 3.0 mg/dL with a conjugated bilirubin less than 0.5 mg/dL;Now Total bilirubin ≤ 1.5 × ULN.
    Exclusion criteria
    • ChangedBefore Active central nervous system (CNS) leukemia. For patients with a history of CNS leukemia, a lumbar puncture should be performed during screening to exclude the presence of active CNS involvement.Now Active central nervous system (CNS) leukemia.
    • AddedPrior history of allogeneic hematopoietic transplantation:
    • EditedAllogeneicIn Parts A, B, and C: Prior history of allogeneic hematopoietic transplantation within six months of treatment, or with clinical or laboratory evidence of GVHD, or requiring ongoing treatment with immune suppression within 2 months of the first dose of CLN-049.
    • AddedIn Parts D and E: Prior history of allogeneic hematopoietic transplantation within twelve months of treatment or with clinical or laboratory evidence of GVHD, or requiring ongoing treatment with immune suppression
    • EditedRadiation therapy (XRT) within 28 days of the first dose of CLN049CLN-049, or craniospinal XRT within 8 weeks of the first dose of CLN-049, or history of total body irradiation (TBI).
    • EditedSystemic glucocorticoid therapy (except equivalent of < 10 mg prednisone daily) or other immune-suppressive drugs ≤ 14 days prior to the first dose of CLN-049 (see separate guidelines for patients who are post allogeneic hematopoietic transplantation). The transient use of corticosteroids for transfusion premedication or the treatment of infusion or transfusion reactions will not be considered for this criterion. Topical corticosteroids and steroid eye drops are allowed, and will not exclude the patient from eligibility.
    • EditedPatients with any active autoimmune disease or a history of known or suspected autoimmune disease, or history of a syndrome that requires systemic corticosteroids or immunosuppressive medications, except for patients with vitiligo, psoriasis (in consultation with the Sponsor), resolved childhood asthma/atopy or autoimmune thyroid disorders on stable thyroid hormone supplementation.
    • EditedActive uncontrolled infection within seven days of first dose of CLN-049. Prophylactic use of systemic antiviral, antibacterial, or antifungal agents for treatment of chronic, controlled infection or as prophylaxis is permitted.
    • EditedKnown history of hepatitis B (with positive testing for either hepatitis B surface antigen [HBsAg] or hepatitis B core Ab), hepatitis C (HCV) infection (with positive testing for HCV antibody and/or HCV ribonucleic acid [RNA] in serum), or acute hepatitis A (with positive testing for hepatitis A IgM). Note: patients with chronic HCV with undetectable viral load defined by sustained virologic response 24 weeks (SVR24) after completion of anti-hepatitis C treatment will be eligible. Patients with hepatitis B surface antigen [HBsAg] or hepatitis B core Ab with negative viral load will be eligible.
    • ChangedBefore Active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection including history of positive SARS-CoV-2 testing without subsequent documentation of negative test results, patients with results that are pending but not yet known, or patients with suspected active infection based on clinical featuresNow Active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
    • RemovedWoman of child-bearing potential (WOCBP) who is pregnant or breast-feeding, plans to become pregnant within 120 days of last study drug administration, or declines to use an acceptable method to prevent pregnancy during study treatment and for 120 days after the last dose of study drug administration.
    • RemovedMale patient who plans to father a child or donate sperm within 120 days of last study drug administration, or who has a partner who is a WOCBP, and declines to use acceptable method to prevent pregnancy during study treatment and for 120 days after the last dose of study drug administration.
    • RemovedKnown active alcohol or drug abuse.
    • RemovedPatients who are incapacitated or involuntarily incarcerated.
    Primary outcomes 1 time frame changed, 1 added
    What changed in the outcomes
    • AddedEfficacy of CLN-049Time frame: Up to 13 weeks
    • Time frameCmax of CLN-04928 Days → Up to 13 weeks
    Secondary outcomes 1 removed
    What changed in the outcomes
    • RemovedImmunogenicity of CLN-049Time frame: 28 days
    Interventions Arms added: Part D - Phase 2 Dose Optimization and Expansion·Part E - Expansion of IV-administered CLN-049 in newly diagnosed AML patients with TP53 mutations
    Design Added Phase 2
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Emory University Hospital · Atlanta, United StatesContact person changed (no phone or email listed)
    + 5 other changes: identifiers, verification date, oversight details, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05143996
Lead sponsor
Cullinan Therapeutics Inc.
Responsible party
Sponsor
First posted
Dec 3, 2021
Start date
Nov 18, 2021
Primary completion
Dec 30, 2029 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
Oct 28, 2026

Study contacts

Timna Serino
Contact
ClinOps@cullinantx.com
+1 617 410 4650

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion